Skip to main content

Table 2 Comorbidity characteristics of total patient population

From: Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database

 

ADL

IFX

SCK

UST

Total

Number of patients

42 (100%)

52 (100%)

21 (100%)

90 (100%)

205 (100%)

Obesity

0 (0%)

0 (0%)

0 (0%)

1 (1.1%)

1 (0.5%)

Diabetes without complication/comorbidity

2 (4.8%)

4 (7.7%)

0 (0%)

6 (6.7%)

12 (5.9%)

Diabetes with complication/comorbidity

0 (0%)

2 (3.8%)

1 (4.8%)

4 (4.4%)

7 (3.4%)

Hypertension

6 (14.3%)

11 (21.2%)

4 (19.0%)

28 (31.1%)

49 (23.9%)

Hyperlipidemia

8 (19.0%)

13 (25.0%)

5 (23.8%)

20 (22.2%)

46 (22.4%)

Subsequent/old myocardial infarction

0(0%)

1 (1.9%)

0(0%)

1 (1.1%)

2 (1.0%)

Heart failure

2 (4.8%)

4 (7.7%)

0 (0%)

8 (8.9%)

14 (6.8%)

  1. ADL Adalimumab, IFX Infliximab, SCK Secukinumab, UST Ustekinumab, DLMOL Disorders of lipoprotein metabolism and other lipidemias